Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Apr 4;12(4):324.
doi: 10.3390/pharmaceutics12040324.

Antifungal and Antiparasitic Drug Delivery

Affiliations
Editorial

Antifungal and Antiparasitic Drug Delivery

Juan José Torrado et al. Pharmaceutics. .

Abstract

Fungal and parasitic diseases affect more than a billion people across the globe, one-sixth of the world's population, mostly located in developing countries. The lack of effective and safer treatments combined with a deficient diagnosis lead to serious chronic illness or even death. There is a mismatch between the rate of drug resistance and the development of new medicines. Formulation of antifungal and antiparasitic drugs adapted to different administration routes is challenging, bearing in mind their poor water solubility, which limits their bioavailability and efficacy. Hence, there is an unmet clinical need to develop vaccines and novel formulations and drug delivery strategies that can improve the bioavailability and therapeutic effect by enhancing their dissolution, increasing their chemical potency, stabilising the drug and targeting high concentration of drug to the infection sites. This Editorial regards the ten research contributions presented in the Special Issue "Antifungal and Antiparasitic Drug Delivery".

Keywords: amphotericin B; aspergillosis; azoles; candidiasis; combined therapy; emulsions; leishmaniasis; liposomes; malaria; nanoparticles; quality by design; transferosomes; trypanosomiasis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Téllez-Martínez D., Portuondo D.L., Loesch M.L., Batista-Duharte A., Carlos I.Z. A recombinant enolase-Montanide™ Petgel A vaccine promotes a protective Th1 immune response against a highly virulent Sporothrix schenckii by toluene exposure. Pharmaceutics. 2019;11:144. doi: 10.3390/pharmaceutics11030144. - DOI - PMC - PubMed
    1. Alexandrino-Junior F., Holanda e Silva K.G., Freire M.C.L.C., Lione V.O.F., Azevedo Cardoso E., Marcelino H.R., Genre J., Gomes de Oliveira A., Egito E.S.T. A functional wound dressing as a potential treatment for cutaneous leishmaniasis. Pharmaceutics. 2019;11:200. doi: 10.3390/pharmaceutics11050200. - DOI - PMC - PubMed
    1. Sosa L., Calpena A.C., Silva-Abreu M., Espinoza L.C., Rincón M., Bozal N., Domenech O., Rodríguez-Lagunas M.J., Clares B. Thermoreversible gel loaded amphotericin B for the treatment of dermal and vaginal candidiasis. Pharmaceutics. 2019;11:312. doi: 10.3390/pharmaceutics11070312. - DOI - PMC - PubMed
    1. Becerra-Sousa A., Fernández-García R., Rodrígues G.F., Bolás-Fernández F., Laurenti M.D., Passero L.F., Lalatsa A., Serrano D.R. Repurposing butenafine as an oral nanomedicine for visceral leishmaniasis. Pharmaceutics. 2019;11:353. doi: 10.3390/pharmaceutics11070353. - DOI - PMC - PubMed
    1. Serrano D.R., Fernández-García R., Mele M., Healy A.M., Lalatsa A. Designing fast-dissolving orodispersible films of amphotericin B for oropharyngeal candidiasis. Pharmaceutics. 2019;11:369. doi: 10.3390/pharmaceutics11080369. - DOI - PMC - PubMed

Publication types

LinkOut - more resources